Feature | August 28, 2014

SCAI Publishes Expert Consensus Recommendations for Treatment of Renal Artery Stenosis

Fourth paper in series reviews treatments for patients often excluded from clinical trials

August 28, 2014 — Renal artery stenting to open blockages in the kidney arteries may benefit patients who have historically been excluded from modern clinical trials, according to new recommendations published online in Catheterization and Cardiovascular Interventions by the Society for Cardiovascular Angiography and Interventions (SCAI).

Blockages in the renal arteries are often asymptomatic, but may lead to high blood pressure or worsening of high blood pressure control. If left untreated, the disease can cause kidney failure and heart failure. Optimal medical therapy remains the preferred first-line treatment.

For patients whose condition is not controlled by medication, treating blocked arteries with angioplasty and stenting may help reduce blood pressure and prevent progression of the disease. Recent randomized controlled trials, including the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial, have failed to demonstrate benefit of renal stenting over optimal medical therapy. However, there were patients whose condition might be improved by renal artery stenting who were excluded from the trial.

“The CORAL trial answered many of our questions about renal artery stenting, but some patients who are seeking treatment today were not included in CORAL, including patients in whom optimal medical therapy failed,” said Sahil A. Parikh, M.D., FSCAI, assistant professor of medicine, Case Western Reserve University School of Medicine, director, Interventional Cardiology Fellowship Program, University Hospitals Case Medical Center, and the paper’s lead author. “The new recommendations were developed to help physicians evaluate treatment options for the broad range of patients with renal artery disease.”

Based on an expert panel review of scientific data, the document recommends that patients most likely to benefit from renal artery stenting are those with cardiac disturbance syndrome or “flash” pulmonary edema (the rapid onset of fluid buildup in the lungs); patients whose high blood pressure has not been controlled by three or more medications at maximal tolerated doses; and those with blockages in both kidneys or severe blockages in a single functioning kidney where blood pressure or renal dysfunction cannot be managed medically.

In contrast, the expert panel recommends that patients with mild or moderate blockages (less than 70 percent), those with long-standing loss of blood flow and those with complete blockage of the renal artery are typically not good candidates for renal artery stenting. It is unknown whether renal artery stenting can improve symptoms in patients with heart failure over the long term.

In addition, the expert consensus statement reviews the evidence and expert opinion on the performance of renal artery angiography and intervention with stents. The panel delineates the best practices for assessing arterial narrowing that is intermediate (i.e. 50-70 percent), which often does not limit blood flow.

“Most practicing physicians performing these procedures will find this guidance particularly helpful in assessing renal artery disease in the future,” said Parikh.

The paper is the fourth in a series of recommendations developed by SCAI on treatment for peripheral artery disease (PAD). The incidence of PAD is growing, and the series aims to help interventional cardiologists determine the best course of treatment for patients whose blocked arteries place them at risk of reduced blood flow that can lead to loss of a limb or organ damage.

“As our understanding of PAD and its treatment options grows, physicians have the ability to improve symptoms and quality of life for many more patients today,” said SCAI 2014-15 President Charles Chambers, M.D., FSCAI. “Our series of treatment recommendations is designed to help interventional cardiologists provide the best possible care based on each patient’s individual symptoms and condition.

For more information: www.scai.org

Related Content

Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents | January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents | November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
OCT stent strut coverage

OCT imaging showing neointimal tissue coverage of metallic stent struts.

News | Stents | November 07, 2016
November 7, 2016 – Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init